Found: 1
Select item for more details and to access through your institution.
ISL1 predicts poor outcomes for patients with gastric cancer and drives tumor progression through binding to the ZEB1 promoter together with SETD7.
- Published in:
- Cell Death & Disease, 2019, v. 10, n. 2, p. 1, doi. 10.1038/s41419-018-1278-2
- By:
- Publication type:
- Article